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Abstract   
Background: Mucopolysaccharidoses (MPSs) are a group of lysosomal storage diseases, resulted from 
glycosaminoglycans’ breakdown failure (GAGs). The study aims to determine the presence of thrombocytopenia, its 
prevalence, clinical implication, and correlation with the types of MPSs and with the types of glycosaminoglycans 
storage. 
Methods: A retrospective cross-sectional study of complete blood count data was conducted among 108 children with 
a confirmed diagnosis of MPS in the National Medical Research Center for Children's Health, Moscow, Russian 
Federation. STATISTICA 10 (Stat Soft, Inc. 1984-2011) was used for statistical analysis. A p-value of ≤0.05 was 
considered significant. 
Results: The median age of children was 65 [IQR: 41; 102] months, range: 3 – 102 months. The male to female ratio 
was 3:1. The prevalence of fluctuating or persistent thrombocytopenia in all children with MPS was 19.0%. 
Thrombocytopenia occurred in patients with MPS I (14.0%), II (19.0%), and III (31.0%). Neither of the patients with 
MPS IV nor VI demonstrated low platelet count. There was a non-significant predominance (P=0.068) of 
thrombocytopenia frequency in patients with heparan sulfate storage (22.0%) compared with patients without heparan 
sulfate burden (0%). 
Conclusion: Routine checkups of patients with MPSs must include complete blood count with platelet measurement. 
Cases of thrombocytopenia that requiring treatment, immunomodulatory/ immunosuppressive therapy should be 
considered. Further research is needed to look for the laboratory confirmation of autoimmune variants of HIT in 
patients with MPS I, II, III. 
Keywords: Mucopolysaccharidoses, Glycosaminoglycans’ Storage, Heparan Sulfate, Autoimmune 
Thrombocytopenia, Moscow, Russian Federation 
 
Background  
Mucopolysaccharidoses (MPSs) are a group of multisystem 
metabolic diseases resulting from deficiency of the Lysosomes 
enzymes involved in glycosaminoglycans’ breakdown. The 
classical clinical picture of mucopolysaccharidoses does not 
comprise thrombocytopenia. Nevertheless, less increasing 
number of case reports describing thrombocytopenia in patients 
with Hunter and Sanfilippo syndromes [1-9] and even in a child 
with unspecified type of MPS [10] have appeared in recent 
years. Some of the articles described clinical manifestations of 
thrombocytopenia, including serious complications: intracranial 
hemorrhage, recurrent epistaxis, melena and anemia, extradural 
hemorrhage following ventriculoperitoneal shunt insertion, 
intraoperative bleeding during adenoidectomy, epistaxis, and 
skin hemorrhages [1, 3, 6, 7, 8, 10]. Notably, most cases of low 
platelet count were encountered in patients with heparan sulfate 
breakdown failure (namely MPS II and III). Thus, the present 
study aims to analyze thrombocytopenia prevalence, its clinical 
implication, and correlation with the MPSs’ and 




Design of study   
A retrospective cross-sectional study was conducted from 
January 2007 to December 2016 at the National Medical 
Research Center for Children's Health to reveal 
thrombocytopenia in a group of children with MPSs (n=108). 
 
Inclusion and exclusion criteria  
All children with enzymatically and molecularly confirmed 
diagnoses of one of the MPSs’ types were included in the study. 
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There were no exclusion criteria for the patients with confirmed 
MPS.  
 
Procedures   
Data on complete blood count were retrospectively searched 
through the medical charts, recorded in National Medical 
Research Center for Children's Health, and through medical 
records provided from regional medical institutions. Clinical 
implications of thrombocytopenia were thoroughly explored 
through all medical charts. One or more complete blood count 
measures were available for each of the 108 children. All 
samples independently of the presence of pathogenic therapy 
(regular enzyme-replacement therapy or exposure to 
hematopoietic stem cell transplantation) were used for analysis. 
However, we excluded the measures obtained during acute 
respiratory infections, after epileptic status or surgery, and those 
low platelet count measures suspicious of adverse drug events. 
 
Definition of variables  
Patients having one or more platelets count less than 150х109/L 
were considered thrombocytopenia cases. To evaluate the 
influence of the type of accumulated glycosaminoglycan on the 
development of thrombocytopenia, we analyzed the prevalence 
of thrombocytopenia in subgroups of patients with different 
types of MPSs. In respect to all published cases of 
thrombocytopenia included only patients with MPS II and III, 
we separately compared the prevalence of discussed disturbance 
in the subgroups of patients with and without heparan sulfate 
storage that is considered to have structural and functional 
similarity to heparin. 
 
Statistical analysis   
We analyzed the frequency and values of thrombocytopenia in 
the whole group of children, in patients with different types of 
MPSs, and the groups with and without heparan sulfate storage. 
For descriptive statistic calculations, we used the minimal 
values of platelets’ count (fixed for every patient during 
dynamic observation). Prevalence of thrombocytopenia in 
different types of MPSs was represented as absolute and 
relative frequency. Descriptive statistics of platelet count were 
expressed as medians, interquartile ranges, minimum and 
maximum. Fisher's two-tailed exact test was used to evaluate 
the difference between thrombocytopenia frequency in different 
types and groups of MPSs. We used STATISTICA 10 (Stat 
Soft, Inc. 1984-2011) for calculations. A P-value of ≤0,05 was 
considered statistically significant. 
 
Results   
One hundred eight children with enzymatically and molecularly 
confirmed diagnosis of one of the MPSs’ types were evaluated. 
9 patients had MPS I Hurler, 4 – MPS I Hurler-Scheie, 1 –MPS 
I Scheie, 53 – MPS II, 26 – MPS III, 6 – MPS IVA, 9 – MPS 
VI. There were 26 female and 82 male patients. All patients 
with MPS II were males. The median age of children at the time 
of the first admission to the National Medical Research Center 
for Children's Health was 65 [IQR: 41; 102] months, minimum 
– 3 months, maximum – 102 months. Out of 108 children 20 
(19.0%) demonstrated fluctuating or persistent 
thrombocytopenia. There was no significant difference in the 
frequency of thrombocytopenia among different types of MPSs 
(Table1). 
Table 1 Thrombocytopenia in children with different types of mucopolysaccharidoses (N=108) 
Type of MPS Number of patients Frequency of thrombocytopenia§ Platelet count, х109/L* 
MPS I 14 2/14 (14%) 77; 0 
MPS II 53 10/53 (19%) 
135 [116;139] 
98-145 
MPS III 26 8/26 (31%) 
107 [89;134] 
82-147 
MPS IVA 6 0/6 (0%) - 
MPS VI 9 0/9 (0%) - 
Footnote.*median [IQR], min-max platelet count, that is beyond the reference range. §Comparing frequency in different types does not show significant difference. 
 
Although apparent excess of thrombocytopenia frequency, 
however there was no statistically significant difference 
(p=0.068) among group of patients with MPSs, in which 
heparan sulfate breakdown failure occurs (22.0%), compared 
with those without heparan sulfate storage (0%) (Table 2).  
Only 4 of 20 (20.0%) children, who had thrombocytopenia, 
experienced compatible clinical signs, presented as bleeding 
after tooth extraction in a girl with MPS IIIA, easy bruising and 
subdural hemorrhage – in a male with MPS IIIB, skin 
hemorrhages, and hematochezia in the neonatal period – in a 
male with MPS II. A male with Hurler syndrome, 2.5 months 
old, had a platelet count drop to an undetectable level; the 
clinical signs consisted of petechial rash. Clinical and 
laboratory manifestations resolved after intravenous 
immunoglobulin therapy. 
 
Discussion   
Despite a growing number of case reports describing 
thrombocytopenia in patients with MPSs, there is no single 
opinion about its pathogenic mechanism. Hypersplenism and 
substrate storage in bone marrow, as in Gaucher disease, are 
supposed to be the main causal factors by some researchers [4, 
11-13]. To the best of your knowledge Us B. et al. [9] were the 
first and the only to consider an immune-mediated mechanism 
and/or possibly chronic antigenic stimulation due to GAG 
accumulation as the etiological factor of thrombocytopenia in 
MPS II. For the purpose of evolving our conception and 
summarizing the facts, a further discussion would be in this 
section considering the heparin-induced etiology of 
thrombocytopenia in MPSs. Heparin-induced thrombocytopenia 
(HIT) has not yet been discussed and explored in patients with 
these metabolic diseases. HIT is an immune prothrombotic 
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complication of heparin therapy caused by antibodies to 
complexes of platelet factor 4 (PF4) and heparin. HIT 
antibodies may recognize PF4 bound to platelet chondroitin 
sulfate. Activation of platelets even in the absence of heparin, 
can explain spontaneous HIT syndrome (which resembles HIT 
clinically and serologically but occurs without proximate 
heparin exposure) [14]. Explanation of HIT possibility in MPSs 
can be structured as follows. Since the published case reports 
and our data have demonstrated the occurrence of 
thrombocytopenia exclusively in patients with heparan sulfate 
storage (MPS I, II, and III), heparan sulfate may play a 
significant role. As heparan sulfate is known to have structural 
and functional similarity to heparin [15-17], a well-known 
entity, called HIT, should be considered. Most research 
[1,6,7,9,10] reported the efficacy of 
immunomodulatory/immunosuppressive therapy (intravenous 
immunoglobulin and corticosteroids) for thrombocytopenia in 
MPS II and III patients and encountered in one of our patients, 
is in accordance with HIT. Furthermore, cases of spontaneous 
HIT after orthopedic surgery have been described and judged to 
be the result of glycosaminoglycans’ release, triggering the 
generation of complexes with PF4 and subsequent antibody 
production [18-22]. In addition, the emergence of 
thrombocytopenia after cessation of enzyme replacement 
therapy in two patients with Hunter syndrome, presented by 
Jurecka A, et al. [23] point out to the link between hematologic 
disturbance and increased glycosaminoglycans' amount in the 
blood. 
Thus, the autoimmune variant of HIT is a probable 
manifestation of MPSs with heparan sulfate storage. This 
theoretical suggestion determines the need to investigate 
antibodies to PF4/heparin complexes, heparin-induced platelet 
aggregation, and serotonin release in patients with MPS I, II, 
and III. Determination of other predisposing factors, such as 
HLA alleles and killer-cell immunoglobulin-like receptors [23], 
would be of great interest.  
 
Table 2 Heparan sulfate influence on the development of thrombocytopenia (N=108) 
Glycosaminoglycans’ storage type  Number of patients Frequency of thrombocytopenia Platelet count, х109/L* 
MPS I, II, III (with heparan sulfate 
storage) 
93 20/93 (22%)§ 
121 [95;139] 
0-147 
MPS IVA, VI (without heparan sulfate 
storage) 
15 0/15(0%)§ - 
All patients 
108 20/108 (19%) 
121 [95;139] 
0-147 




In conclusion, it is reasonable to state that thrombocytopenia is 
not a rare manifestation in patients with MPS. The autoimmune 
variant of HIT is one of the probable explanations of the 
disturbance. Thus the practical approach to patients with MPS, 
especially I, II, and III, must include regular complete blood 
count with platelet measurement, and 
immunomodulatory/immunosuppressive therapy should be 
considered in cases of thrombocytopenia, requiring treatment. 
Furthermore, additional analysis of laboratory HIT markers in 
MPSs is a perspective of searching new markers of clinical 
manifestations and severity of these lysosomal storage diseases. 
 
Abbreviation  
MPS(s): Mucopolysaccharidosis (es); GAGs: 
Glycosaminoglycans; HIT: heparin-induced thrombocytopenia; 
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